From Yahoo Finance · · 1m 20s
Innate Pharma Q2 Earnings Highlights
Innate Pharma secures $75m Sobi deal for cancer drug.
In brief
Innate Pharma secures $75m Sobi deal for cancer drug. Innate Pharma's Q2 earnings call highlighted a $75 million upfront payment with Sobi for lacutamab, extending cash runway to Q1 2028. Originally reported by Yahoo Finance.
Sobi Partnership Details
Innate Pharma secured a $75 million upfront payment from Sobi for lacutamab, with additional €30 million equity financing.
“Innate Pharma strengthened its finances through a Sobi partnership for lacutamab, including a $75 million upfront payment, and a €30 million equity financing.”
Cash Runway Extension
The partnership and financing extend Innate's cash runway through the end of Q1 2028.
“The company expects its cash runway to extend through the end of Q1 2028.”
Lacutamab Phase III Trial
Lacutamab's TELLOMAK-3 phase III trial begins enrollment in Q1 2027 with potential accelerated approval for Sézary syndrome in H2 2027.
“Lacutamab's phase III TELLOMAK-3 trial has begun, with enrollment expected in Q1 2027 and a potential accelerated-approval filing for Sézary syndrome planned for the second half of 2027.”
Regulatory Designations
Lacutamab received FDA Breakthrough Therapy, Fast Track, EMA PRIME, and orphan-drug designations in the U.S. and Europe.
“Jensen said lacutamab has received FDA Breakthrough Therapy designation for relapsed or refractory Sézary syndrome, as well as FDA Fast Track designation, European Medicines Agency PRIME designation, and orphan-drug designations in the U.S. and Europe.”
Monalizumab Phase III Readout
PACIFIC-9 phase III trial for monalizumab enrolls 1,051 patients with unresectable stage III non-small cell lung cancer.
“Enrollment has been completed in PACIFIC-9, a randomized phase III trial of monalizumab in unresectable stage III non-small cell lung cancer.”
IPH4502 Clinical Data
IPH4502 shows preliminary responses in heavily pretreated solid tumors after prior enfortumab vedotin treatment.
“Innate reported preliminary antitumor activity, including objective responses in heavily pretreated patients with urothelial cancer after prior enfortumab vedotin treatment.”
Next Steps for IPH4502
Innate plans to present initial phase I dose-escalation data at EORTC-NCI-AACR meeting in Barcelona on November 18.
“Innate plans to present initial phase I dose-escalation data at the EORTC-NCI-AACR meeting in Barcelona in November.”
Financial Position
Innate has €21.4 million cash equivalents as of June 30, 2026, excluding €65 million Sobi payment and €30 million equity offering.
“Chief Financial Officer Frédéric Lombard said Innate had €21.4 million in cash equivalents and financial assets as of June 30, 2026.”
What matters most
Innate Pharma's Q2 earnings call highlighted a $75 million upfront payment with Sobi for lacutamab, extending cash runway to Q1 2028.
